Risk factor
Poor trading liquidity
Profitability factor
Favourable price performance
About
ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services....
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT
Target Price
The average target price of 1789.TW is 18 and suggests 17% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de
Buy
Sell